Maplight Therapeutics Common Stock Performance
| MPLT Stock | 17.57 0.59 3.47% |
On a scale of 0 to 100, MapLight Therapeutics holds a performance score of 5. The company secures a Beta (Market Risk) of 2.01, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MapLight Therapeutics will likely underperform. Please check MapLight Therapeutics' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether MapLight Therapeutics' current price movements will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in MapLight Therapeutics Common are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent essential indicators, MapLight Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 8.15 | Five Day Return (1.28) | Year To Date Return 1.25 | Ten Year Return (7.42) | All Time Return (7.42) |
1 | Maplight Therapeutics Stock Rating Upgraded by Zacks Research | 11/26/2025 |
2 | Maplight Therapeutics Raised to Hold at Wall Street Zen | 12/22/2025 |
3 | Maplight Therapeutics Trading Up 10.5 percent Whats Next | 01/13/2026 |
4 | Insider Selling Maplight Therapeutics Director Sells 7,0 Shares of Stock | 02/05/2026 |
MapLight Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,507 in MapLight Therapeutics Common on November 11, 2025 and sell it today you would earn a total of 214.00 from holding MapLight Therapeutics Common or generate 14.2% return on investment over 90 days. MapLight Therapeutics Common is currently generating 0.3806% in daily expected returns and assumes 6.0387% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than MapLight, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MapLight Therapeutics Target Price Odds to finish over Current Price
The tendency of MapLight Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 17.57 | 90 days | 17.57 | about 40.17 |
Based on a normal probability distribution, the odds of MapLight Therapeutics to move above the current price in 90 days from now is about 40.17 (This MapLight Therapeutics Common probability density function shows the probability of MapLight Stock to fall within a particular range of prices over 90 days) .
MapLight Therapeutics Price Density |
| Price |
Predictive Modules for MapLight Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as MapLight Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.MapLight Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. MapLight Therapeutics is not an exception. The market had few large corrections towards the MapLight Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold MapLight Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of MapLight Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.0049 | |
β | Beta against Dow Jones | 2.01 | |
σ | Overall volatility | 2.17 | |
Ir | Information ratio | 0.01 |
MapLight Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of MapLight Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for MapLight Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| MapLight Therapeutics had very high historical volatility over the last 90 days | |
| MapLight Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Insider Selling Maplight Therapeutics Director Sells 7,0 Shares of Stock |
About MapLight Therapeutics Performance
Assessing MapLight Therapeutics' fundamental ratios provides investors with valuable insights into MapLight Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MapLight Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.61) | (0.64) |
Things to note about MapLight Therapeutics performance evaluation
Checking the ongoing alerts about MapLight Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MapLight Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MapLight Therapeutics had very high historical volatility over the last 90 days | |
| MapLight Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Insider Selling Maplight Therapeutics Director Sells 7,0 Shares of Stock |
- Analyzing MapLight Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MapLight Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining MapLight Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MapLight Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MapLight Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MapLight Therapeutics' stock. These opinions can provide insight into MapLight Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MapLight Stock Analysis
When running MapLight Therapeutics' price analysis, check to measure MapLight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MapLight Therapeutics is operating at the current time. Most of MapLight Therapeutics' value examination focuses on studying past and present price action to predict the probability of MapLight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MapLight Therapeutics' price. Additionally, you may evaluate how the addition of MapLight Therapeutics to your portfolios can decrease your overall portfolio volatility.